As gene therapy and gene editing technologies improve, greater focus should be placed on techniques and procedures for treating heritable illnesses while respecting ethical norms. We're currently in the second cycle of public perception of gene therapy. During the 1990s gene therapy boom, the first surge of enthusiasm came to an end when the first gene therapy death occurred in 1999. While there are parallels between then and today in the public and scientific zeitgeist, the recall of earlier blunders has poisoned this assessment. Some are more recent, such as the 2018 announcement of germline-edited offspring, and stir up many more ethical arguments than this study can investigate.Despite academic disputes about the future of heritable genome editing, we are reaching a golden age of somatic gene therapy, with over 1,600 research presently active or recruiting patients. However, for both somatic and germline-based therapies, one thing appears to be universal: the scientific community must include the public and seek some type of broad societal discussion or consensus on widespread clinical use of gene editing. Governments should move promptly to provide public education on the scientific and ethical elements of genetic problems, allowing for national debate and universal consensus before legislation is enacted. These laws should seek to clarify ethical issues and reduce difficulties that may arise from somatic or germline genome editing, such as regulating the pricing of such medicines to make them affordable to all. After reviewing existing HHGE legislation worldwide, something like general societal agreement is already building, with 72 percent of nations exploring prohibiting HHGE. Currently, no country has legally authorized genome editing in vivo. Of course, this could change, especially as many nations begin to engage in a deeper dialog about HHGE with experts and the general public.What happens next will decide whether we can pursue this life-changing science responsibly or whether the dark matter of gene therapy, including ethical violations, will continue to plague the industry, leading to fresh cycles of hope, failure, and moratoriums.